Opinion

Video

Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • For a patient who does not receive second-line cellular therapy whether based on logistical or clinical reasons, what would be your choice of approved therapies?
      • When choosing a second-line therapy for a patient not eligible for transplant or CAR T-cell therapy, what most impacts your decision? Drug approval? NCCN guidelines? Based on what first-line treatment was received?
    • Please review the final 5-year data of the L-MIND study evaluating tafasitamab + lenalidomide.

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data

    Related Content